Lesley Portnoy and Clinical Data

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Globe Newswire | 10/14/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against electroCore, Inc. | Business Wire | 10/2/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use of gammaCore, the Company’s treatment for pain associated with episodic …

Glancy Prongay & Murray LLP Files Securities Class Action on Behalf of electroCore, Inc. Investors – Company Announcement - FT.com | Financial Times | 9/27/2019

… on September 25, 2019 , the Company revealed that the U.S. Food and Drug Administration requested more information and analysis of clinical data for electroCore’s 510(k) submission, which seeks an expanded indication for the use … rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire , of GPM, 1925 Century Park East, Suite 2100, Los Angeles, California 90067 at 310-201-9150, Toll-Free at 888-773-9224, by email to shareholders …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Helius Medical Technologies, Inc. | Globe Newswire | 9/4/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … the PoNS device because the Company had not provided sufficient clinical data to show the device was effective. On this news, shares of Helius fell $4.11, or more than 66%, to close at $2.10 per …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Helius Medical Technologies, Inc. | Business Wire | 7/16/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … the PoNS device because the Company had not provided sufficient clinical data to show the device was effective. On this news, shares of Helius fell $4.11, or more than 66%, to close at $2.10 per …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc. | Globe Newswire | 6/11/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … fenfluramine, and the application contained an incorrect version of a clinical dataset. On this news, shares of Zogenix fell $11.89 or nearly 23% to close at $39.96 per share on April 9, 2019, thereby injuring …

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Zogenix, Inc. | Business Wire | 5/3/2019

… if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire, at 310-201-9150, Toll-Free at 888-773-9224, or by email to [email protected] … fenfluramine, and the application contained an incorrect version of a clinical dataset. On this news, shares of Zogenix fell $11.89 or nearly 23% to close at $39.96 per share on April 9, 2019, thereby injuring …